Table 2 Best response of Surufatinib in different solid tumors.

From: Real world study on efficacy and safety of surufatinib in advanced solid tumors evaluation

Type of tumor

No. Of patients(n)

CR

PR

SD

PD

ORR(%)

DCR(%)

Pancreatic neuroendocrine tumor

9

0

3

3

3

33.3

66.7

Non-pancreatic neuroendocrine tumor

7

0

1

2

4

14.3

42.3

Other tumors

12

0

1

2

9

8.3

25.0

  1. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.
Back to article page